Overview
AGMB market data
Price History
AGMB price chart
Valuation & Profitability
No Valuation Data Yet
Alpha Vantage and Twelve Data both returned no valuation metrics for AGMB. Check back after the next daily valuation refresh — this symbol may be new, delisted, or temporarily unavailable from both providers.
Company news
AgomAb Therapeutics shares are trading higher after B. Riley Securities initiated its coverage on the stock with a Buy rating and announced a price target of $34.Benzinga · Jul 23, 2026, 5:31 PM
B. Riley Securities Initiates Coverage On AgomAb Therapeutics with Buy Rating, Announces Price Target of $34Benzinga · Jul 23, 2026, 2:13 PM
Agomab Therapeutics Aligns With FDA On Design Of Phase 2b NOV-ERA Study With Ontunisertib;=Benzinga · Jun 23, 2026, 8:15 PM
This Apple Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For MondayBenzinga · Jun 22, 2026, 4:10 PM
This Credo Technology Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For MondayBenzinga · Jun 22, 2026, 12:40 PM
HC Wainwright & Co. Initiates Coverage On AgomAb Therapeutics with Buy Rating, Announces Price Target of $35Benzinga · Jun 22, 2026, 11:05 AM
Agomab Announces Results of Annual General MeetingGlobenewswire Inc · May 27, 2026, 11:01 AM